oxcarbazepine (SPN-604) / Supernus Pharma - LARVOL DELTA

Novel Hormonal Therapies in Prostate Cancer - Episode 2: Case 1: A 59-Year-Old Man With Nonmetastatic CRPC (Targeted Oncology) - "Alan Bryce, MD: We're going to move on to case No. 1. I'm going to hand this off to Dr Efstathiou. Eleni Efstathiou, MD, PhD: Thank you very much. Alan and Daniel [Landau], it's great to be with you. Thank you for having me. Let's talk about our patients and the cases we deal with every day....At that point, the decision was made to initiate androgen deprivation, and a depot leuprolide of 45 mg for 6 month dosage was given. The patient transferred his care, and the PSA nadir is unknown at that point."

Video

Supernus announces first quarter 2020 financial results (BioSpace) - "The Company has reprioritized its research and development (R&D) resources....These product candidates include SPN-820 from the Navitor partnership.... As a result, and given other factors including the estimated timing of a potential launch of SPN-604 and the required investment, the Company is terminating development of SPN-604 for the treatment of bipolar disorder."

Discontinued • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry